Related Experiment Videos
Pancreatic and nephrotoxicity of immunomodulator compounds
1Astra, Safety Assessment, Astra Charnwood, Loughborough, Leicester, UK.
Abstract:
Increasing clinical experience of FK 506 in transplantation therapy has revealed a number of potentially restrictive adverse effects associated with its use. The mechanisms of action underlying 2 prominent toxic effects of FK 506, namely diabetogenesis and renal dysfunction, were investigated. A simple model system based on the effect of FK 506 on isolated rat pancreatic islets was utilised to study the relationship between inhibition of insulin biosynthesis, inhibition of interleukin 2 (IL-2) activation and FK binding protein (FKBP-12) binding of FK 506 and a number of FK 506 analogues. Results indicate that the action of these compounds on inhibition of insulin biosynthesis (and by implication, diabetogenesis) may be related to their immunosuppressive potential. Observations on the FK 506-induced release of endothelin-1 from isolated rat kidney mesangial cells suggest that this cell may be an important target associated with the nephrotoxic potential of the drug, and that this action may be mediated via the FKBP.
Insights
FK 506 (tacrolimus) can cause diabetes and kidney problems in transplant patients. Its effects on insulin production and kidney cells may be linked to its immunosuppressive properties and FKBP binding.
Area of Science:
- Immunopharmacology
- Transplantation Medicine
- Nephrology
Background:
- FK 506 (tacrolimus) is a widely used immunosuppressant in transplantation.
- Adverse effects, including diabetogenesis and nephrotoxicity, limit its clinical application.
- Understanding the molecular mechanisms of these toxicities is crucial for patient management.
Purpose of the Study:
- To investigate the mechanisms of FK 506-induced diabetogenesis and renal dysfunction.
- To explore the relationship between FK 506's immunosuppressive activity and its toxic effects.
- To identify potential cellular targets and mediators of FK 506's nephrotoxicity.
Main Methods:
- Utilized isolated rat pancreatic islets to study insulin biosynthesis and FK 506 analogue binding.
- Assessed inhibition of interleukin-2 (IL-2) activation as a measure of immunosuppressive potential.
- Examined FK 506-induced endothelin-1 release from isolated rat kidney mesangial cells.
Main Results:
- Inhibition of insulin biosynthesis by FK 506 analogues correlated with their immunosuppressive potential, suggesting a link to diabetogenesis.
- FK 506 induced the release of endothelin-1 from kidney mesangial cells.
- FKBP binding appears to mediate FK 506's action on kidney mesangial cells.
Conclusions:
- The diabetogenic potential of FK 506 may be linked to its immunosuppressive mechanisms.
- Kidney mesangial cells are a potential target for FK 506-induced nephrotoxicity, possibly mediated by FKBP.
- Further research into these mechanisms could lead to strategies for mitigating FK 506 toxicity.